Moreover, SNORD13 appeared to be of potential utility in distinguishing symptomatic HD patients from control groups (AD, PP, HS; AUC = 0.953; Figure 3B), as well as pre-HD among controls (AUC = 0.955; Figure 3C), and to a lesser extent, in identifying HTT mutation carriers (AUC: 0.811; Figure 3D). This evidence concerns the gene HTT and Huntington disease.